AGTC files investigational NDA for X-linked retinitis pigmentosa gene therapy – Healio
|
AGTC files investigational NDA for X-linked retinitis pigmentosa gene therapy
Healio Applied Genetic Technologies Corporation has filed an investigational new drug application with the FDA to begin a phase 1/2 clinical trial of its gene therapy candidate for X-linked retinitis pigmentosa, according to a company press release. X-linked … |
